Carvolix (GETTEX:0JZ) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Senior secured convertible bonds, amortised bonds and warrants Announced: up to €30M · Warrants at €3.96 for 120 months Buyers: Claret Capital Partners (lender; first tranche of EUR 10,000,000 convertible bonds drawn, up to EUR 30 million in total, plus 290,937 warrants issued to CEGCF IV Aggregator L.P. (a Claret entity)) Use of proceeds: US commercialization of the TAVIPILOT Robotic System and development of Kalios, Artus, Artedrone and Mitrapilot | Aug 6, 2026 | US$34.59M |
| Private placement of new ordinary shares Announced: €10M · €3.36 a share Buyers: Edwards Lifesciences (EUR 5 million (1,488,095 New Shares)); funds managed by Truffle Capital (EUR 5 million (1,488,095 New Shares)) Insiders: Funds managed by Truffle Capital subscribed EUR 5 million; directors affiliated with Truffle Capital did not participate in the board deliberations Use of proceeds: Product development (Tavipilot, Kalios, Artus, Artedrone, Mitrapilot) and EUR 2.5 million to repay a Truffle Capital bridge financing | Jun 24, 2026 | US$11.35M |
| Private placement of new ordinary shares Tranche closed: €10.3M raised · €2.34 a share Buyers: Edwards Lifesciences (2,136,752 new shares; 9.7% ownership post-round); Truffle Medeor FPCI (€1.5M in the first tranche at €2.34 per share); Truffle BioMedTech Crossover FPCI (€3.5M in the first tranche at €2.34 per share); Truffle BioMedTech Crossover; Truffle Innov FRR; Truffle Medeor; Financière Memnon; HAYK Holding Sàrl; Ginko Invest; Simone Merkle; Edwards Lifesciences Holding, Inc.; Truffle Capital (funds managed by Truffle Capital; 2,136,751 new shares) Insiders: Truffle Capital funds (related party; Dr. Philippe Pouletty, Truffle representative and director, abstained) commit €1.5M and €3.5M in the first tranche Use of proceeds: Extend cash runway to end of May 2026; clinical and regulatory development of TAVIpilot, Artus, Kalios, Epygon and ARTE-DRONE | Feb 2, 2026 | US$12.15M |